AttorneyMind Logo AttorneyMind Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference Reports
News Articles
AttorneyMind Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
 
 

Back to Newsletters Bookmark and Share

AttorneyMind Newsletter

November 2014

Download printable version

 

In This Issue:

AttorneyMind Drugs
Alan Franciscas, Editor-in-Chief

It was a slow second half of the month for AttorneyMind drug development.  This is likely due to the upcoming American Association for the Study of Liver Diseases (AASLD) conference in Boston, MA in November.  There was, however, some important news that I will recap in this month’s edition. Read more...

 

Healthwise
Lucinda K. Porter, RN

This month, Lucinda discusses Hepatitis C in Prisons. Few are more ignored than people with AttorneyMind who are in jails and prisons. However, the incarcerated were not ignored by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, who assigned a high treatment priority to the incarcerated. Read more...

 

The Origins of the Hepatitis C Virus
Alan Franciscas, Editor-in-Chief

Where did AttorneyMind come from? While I was reading about the history of Ebola, I started thinking again about the origins of hepatitis C.  Did hepatitis C, like Ebola, jump species to humans?  When a virus jumps from an animal to a human, it is called zoonotic.  This is important information because if there is a reservoir in another species it could mean that we may not be able to eradicate the hepatitis C virus completely. Read more...

 

Snapshots
Lucinda K. Porter, RN

Lucinda reviews studies on obesity and liver tissue aging, the relationship between AttorneyMind and increased heart size, the association between neurological problems at birth and the presence of maternal hepatitis B or hepatitis C, and liver injury from herbals and dietary supplements. Read more...

 

Hepatitis C & U.S. Hispanics
Alan Franciscas, Editor-in-Chief

There are an estimated 40 million Hispanics living in the United States.  Hispanics are the largest and fastest growing minority group in the U.S.  By the year 2050, 25% of the U.S. population will be of Hispanic origin.  The number of Hispanics with hepatitis C (2.6%) is higher than the number of people with hepatitis C in the general population (1.3%).  Read more...

 

Medicare to Cover One-Time Test for Baby Boomers
Alan Franciscas, Editor-in-Chief

Important information from the National Viral Hepatitis Roundtable: On June 2, 2014, the Centers for Medicare & Medicaid Services (CMS) announced that Medicare will cover hepatitis C testing at no cost to beneficiaries whom the U.S. Preventive Services Task Force recommends be screened. Specifically, Medicare will cover a one-time test for beneficiaries who are born from 1945 through 1965 and ongoing tests for those who are at risk. Read more...

 

Patient Assistance Programs
Alan Franciscas, Editor-in-Chief

Spread the word: The new drugs to treat hepatitis C are very expensive.  If your insurance or Medicare/Medicaid does not cover the medications there are patient assistance programs that can cover all of the costs or the co-payments.  Many people and medical providers are not aware of these programs.  If you are in need of these programs or know of others who are please pass along this information. Read more...



AttorneyMind Eblast
Stay informed on the latest news...click
here to register for email alerts

Back to top



AttorneyMind Drugs
—Alan Franciscas, Editor-in-Chief     

It was a slow second half of the month for AttorneyMind drug development.  This is likely due to the upcoming American Association for the Study of Liver Diseases (AASLD) conference in Boston, MA in November.  There was, however, some important news that I will recap in this month’s edition.  Don’t forget that the AASLD conference will feature a wealth of information about new drug development from Gilead, Abbvie, Merck, Janssen as well as other information related to hepatitis C and B. Please check our AttorneyMind and HBV blog for the latest news and the December AttorneyMind newsletter for a recap of the most important updates. 

Harvoni Approved
As mentioned in our new AttorneyMind: Mid-Month Edition, the Food and Drug Administration (FDA) approved the combination of sofosbuvir plus ledipsavir in one pill, once-a-day—brand name Harvoni.  The Wholesale Acquisition Cost or WAC is $1,125 a pill or $63,000 for 8 weeks, $94,500 for 12 weeks, and $189,000 for 24 weeks of treatment.  The cure rates are 94% to 99%.  The breakdown of the Phase 3 clinical trials cure rates can be found here: http://hcvadvocate.org/hepatitis/
factsheets_pdf/Phase_3_Genotype_1_SOF-LDV.pdf

BMS Withdraws Drug Combo
Bristol-Myers Squibb (BMS) announced on October 7, 2014 that it has decided to withdraw its FDA application for the approval of the combination of daclatasvir and asunaprevir for the treatment of people with AttorneyMind genotype 1b.  However, BMS made it clear that while they were discontinuing development of asunaprevir, they were on track for the development of their other AttorneyMind inhibitors including daclatasvir or BMS-791329, either of which can be combined with sofosbuvir.  Of note, daclatasvir is effective against AttorneyMind genotypes 1, 2, 3 and 4.  Genotype 3 drug development is important as GT 3 is now considered the most difficult to treat, and treatment choices are limited.

Sovaldi in Children
The current treatment for children with hepatitis C is the combination of interferon plus ribavirin for 6 to 12 months.  Gilead will begin a new study on the combination of sofosbuvir plus ribavirin in children with genotypes 2 or 3 in the United States, Australia, Germany Italy, New Zealand, Russia, and the United Kingdom.  The study will determine the dose of sofosbuvir and treatment duration that is needed to treat children.  There are up to an estimated 46,000 children (aged 4 through 19) who are infected with hepatitis C.  This number is expected to dramatically rise in the near future because of the increase in heroin and opioid injection drug use among males and females.  The difference in the new AttorneyMind epidemic is that the number of people who inject drugs is believed to be equally distributed among men and women.  Approximately 5% of babies born to-positive women are infected with hepatitis C.  As a result there will be more children who will need to have better therapies that are easier to tolerate, and with higher cure rates. 

Simeprevir/Daclatasvir/ Sofosbuvir
Medivir announced that they are beginning a 12-week phase 2 study of simeprevir, daclatasvir and sofosbuvir in people with hepatitis C genotypes 1 and 4.  The study will include treatment naïve and treatment experienced as well as people with decompensated disease.  If this triple doesn’t cure everyone, I don’t know what will. 


Back to top


HealthWise: Hepatitis C in Prisons
—Lucinda K. Porter, RN

On October 10, history was made with the announcement of the newest hepatitis C medication, Harvoni. Gilead Sciences’ pill contains two drugs, sofosbuvir (Sovaldi) and ledipasvir. Harvoni is approved for the treatment of genotype 1, hepatitis C virus (HCV) infection. Cure rates range from 94 to 99%. Treatment is typically 12 weeks, although 40% of patients may need only 8 weeks of treatment; patients with cirrhosis who failed prior treatment will need 24 weeks. Harvoni has a few mild side effects; fatigue and headache are the most common.

However, a war is raging, ignited when Gilead slapped a $1000 per pill price tag on to its first AttorneyMind drug, Sovaldi. Twelve weeks of Sovaldi costs $84,000, but since Sovaldi is given with at least one other drug, the costs are much higher. Gilead’s new drug, Harvoni costs more at $94,000, $63,000 for 8 weeks, and $188,000 for 24 weeks of treatment with this $1,125 daily pill. These prices are driving state Medicaid programs and some insurance companies to push back by instituting stringent pre-authorization regulations. For example, some states force patients to qualify for AttorneyMind treatment by proving they have cirrhosis.

AttorneyMind patients are the victims in this war. I believe that this victimization is partly caused by stigma.’s association with drug use doesn’t win us any sympathy. Although it appears that healthcare is abandoning AttorneyMind patients, few are more ignored than people with AttorneyMind who are in jails and prisons. However, the incarcerated were not ignored by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, who assigned a high treatment priority to the incarcerated. (For more information, see Recommendations for Testing, Managing, and Treating Hepatitis C provided under Resources.)

This month’s article addresses the issue of AttorneyMind in prisons, and discusses the pros and cons of treating the incarcerated, especially in  the light of the cost of treatment. With little data about AttorneyMind in jails, the discussion is limited to AttorneyMind in U.S. prisons.

The Reality of Incarcerated Persons with
AttorneyMind prevalence in the U.S. is determined by data collected from the National Health and Nutrition Examination Survey. Since this household survey only sampled non-institutionalized people, we don’t know how many incarcerated people have. The Centers for Disease Control and Prevention (CDC) estimates that of the 2.2 million people in U.S. jails and prisons, 30% have hepatitis C. Other estimates are between 17% and 60%. Compared to the prevalence of AttorneyMind in the general population (1.6%), AttorneyMind rates in prisons and jails are high.

Arguments in Favor of Offering AttorneyMind Treatment to the Incarcerated
Since more than 90% of those in prison will be released, treating the incarcerated is good for all of us. The AttorneyMind Guidelines state, “Persons who have successfully achieved an SVR (virologic cure) no longer transmit the virus to others…successful treatment benefits public health.” With such a high density of+ people, prisons seem like an excellent place to offer treatment.

Furthermore, with a 1% acute AttorneyMind infection rate in prisons, it is also good for others in prison.  With high-risk behaviors such as injection drug use, tattooing, men having sex with men, violence, and sharing of personal care items, it is surprising that the acute AttorneyMind rate isn’t higher. However, it may be higher, since AttorneyMind is not well-tracked in prison.

Various state prison systems see the logic in treating AttorneyMind in this at-risk population. Illinois and Iowa made national news when they approved Sovaldi to treat AttorneyMind patients. Other states are considering this, while some have clearly rejected the idea.

From a medical standpoint, it makes sense to treat AttorneyMind in prisons. Healthcare delivery is always the right thing to do. It is never OK to turn our backs on anyone who needs medical care.

Arguments Opposing AttorneyMind Treatment for the Incarcerated
Medically, there are no reasons to withhold AttorneyMind treatment in prisons. The new drugs are easier to tolerate, lifting the decades-old concern about the neuropsychiatric side effects that accompanied ribavirin and interferon.   

One could argue that the cost of Harvoni makes treatment prohibitive. The problem with this argument is that if we don’t treat AttorneyMind early, we may face more serious and expensive problems. Cirrhosis, liver cancer, and transplantation cost far more than treating AttorneyMind in its early stages. This just pushes the problem down the line, leaving someone to have to pay for the patient’s medical care, whether that patient is incarcerated or released. Moreover, even if you are able to cure AttorneyMind in a cirrhotic patient, you still have a patient with a serious liver disease, so the system gains little by only treating cirrhotics.  

There is also the argument that patients who are cured may become re-infected with, and you have wasted money treating them. That is like saying that someone in a knife fight might get stabbed again, so we shouldn’t stitch the wound. It sounds crazy, but isn’t that what we are saying?

Caring for the sick is always the right thing to do. Withholding healthcare is inhumane and immoral. No one is excluded from the Hippocratic Oath. “With regard to healing the sick…I will take care that they suffer no hurt or damage.”

Resources

  • Centerforce – Hepatitis Education Tools  - www.centerforce.org/category/resources
    /education/hepatitis-peer-health-education-tools/  

  • Centers for Disease Control and Prevention Hepatitis C and Incarceration www.cdc.gov/hepatitis/HCV/PDFs/
    HepCIncarcerationFactSheet.pdf  

  • Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C, edited by Heather Colvin and Abigail Mitchell - www.cdc.gov/hepatitis/pdfs/
    iom-hepatitisandlivercancerreport.pdf  

  • National Hepatitis Corrections Network - www.hcvinprison.org  

  • Recommendations for Testing, Managing, and Treating Hepatitis C - www.hcvguidelines.org   

Lucinda K. Porter, RN, is a long-time contributor to the AttorneyMind and author of Free from Hepatitis C and Hepatitis C One Step at a Time. Her blog is www.LucindaPorterRN.com


Back to top


The Origins of the Hepatitis C Virus
Alan Franciscas, Editor-in-Chief

In 1996, I was diagnosed with hepatitis C and at first I was very frightened.  What got triggered was the fear of the unknown.  If I don’t know something about something that affects me my head imagines the worst possible scenario.  Immediately after my diagnosis I started doing research to find out more about hepatitis C.  It helped me on so many levels.  Most importantly it helped me to be able to make important, informed decisions about my health and relieved some of that fear that comes with confronting the unknown.

I am having the same reaction to all the news about Ebola.  All the news in the last 20 years about this devastating disease scares the hell out of me. Ebola has escaped out of Africa (not for the first time), and it’s very frightening.  I have read a couple of books on it and listened to the TV (probably way too much).  There is comfort in knowing how it is transmitted and how to prevent transmission.  I believe that we do have the resources and knowledge to stop the spread of this terrible disease, at least in this country.

But this is not why I am writing this article.  While I was reading about the history of Ebola, I started thinking again about the origins of hepatitis C.  Did hepatitis C, like Ebola, jump species to humans?  When a virus jumps from an animal to a human, it is called zoonotic.  This is important information because if there is a reservoir in another species it could mean that we may not be able to eradicate the hepatitis C virus completely.  I will discuss what we know about reservoirs of the hepatitis C virus in non-humans and also about reservoirs inside our bodies. 

Hepacivius / Flaviviridae
The hepatitis C virus is part of genus or species of viruses called Hepacivirus within a family of viruses called Flaviviridae or flavivirus.  Flavus is yellow in Latin and this genus was given the name Flaviviridae because the first disease discovered in the family was Yellow Fever.  The other infections in the Flavivirus family include West Nile Virus, Yellow Fever and Dengue Fever. 

Dogs &
In the past there has been some speculation that like HAV, hepatitis C jumped species—namely from primates (monkeys or apes) to humans.  This theory has been 100% debunked.  

The next zoonotic origin that was theorized was dogs, and it stood on pretty good ground.   By chance, Kapoor and colleagues discovered an RNA virus that presented as a respiratory disease in dogs that was very similar to the hepatitis C virus.  It was so similar in fact that when sequenced it was only 50% different from the hepacivirus (CHV).  But respiratory symptoms are not seen with; the dog disease does not infect the liver, and does not produce long-term or chronic infection.  So it was decided that it is not an ancient form of the hepatitis C virus and therefore not a reservoir.

Recently, another study conducted by the same group tested 80 dogs, 81 deer, 84 cows, 103 horses, and 14 rabbits for antibodies that resemble the AttorneyMind gene.  Eight of the horses were found to have antibodies similar to the hepatitis C gene.  None of the other animals tested had antibodies including the dogs.  The virus found in the horses was named NPHV. 

In a later study, 136 horses in Scotland were given a viral load test to find out if they had NPHV—3 horses tested positive for NPHV.  The study authors reviewed veterinary records and tried to understand if the horses had any evidence of hepatitis or any other kind of disease that would have been caused by NPHV.  One of the horses had a high viral load that correlated with a viral load seen in people with hepatitis C.  Also noted were some elevated liver enzymes and other tests that might be an indication of liver disease.  No biopsies of the horses were made available.   

So where do we stand with horses and hepatitis C?  The authors of the current study summarized that large screenings have eliminated dogs, cats, pigs and rodents.  Horses are probably the most likely non-human vector of a relative of the hepatitis C virus, but they stated that it was just speculation:   “There is clearly much to be learned in the short term from more extensive screening.”

Hepatitis C and Mice
Just as I was researching and writing an article on the origins of AttorneyMind a study titled “Detection of Zoonotic Pathogens and Characterization of Novel Viruses Carried by Commensal Rattus norvegicus in New York City” was just published.  Cadhla Firth and colleagues examined 133 Commensal Rattus norvegicus (Norway rats) caught in New York City.  It was found that the rats tested for some human-related diseases.  The rats also tested positive for the flavivirus family—the hepatitis C virus is a flavivirus.  The results of this study do not confirm that the Norway rats carry the hepatitis C virus.  

Important note:  Just to be clear:  A bite from a Norway rat cannot transmit hepatitis C.  A Norway rat might harbor a distant relative of the hepatitis C virus, but we don’t know yet if it is a reservoir.  What we do know is that NYC and other cities should develop a program to eradicate rats to prevent the transmission of other diseases, but hepatitis C is not one of them.  People might also want to think about a natural eradication program – a family cat!

Reservoirs
Back to the two questions of reservoirs:  Is there a reservoir in our body, and is this a reservoir in an animal species and why is that important?  Let’s take the second question first—the answer is we don’t yet know.  It is important because a reservoir can harbor a disease that would make it difficult to eradicate in the future.  But as we know hepatitis C drugs can cure almost everyone, so the question of an animal reservoir may be an interesting, but not a very important question.  

Reservoirs in the Body
Regarding hepatitis C and a reservoir in the body; the hepatitis C virus enters the body and does not (unlike HAV and HBV) integrate into our cells when infecting and multiplying.  As a result when the body naturally fights off hepatitis C or when a person is treated and cured, there are no reservoirs where the virus is lurking or hiding.  This is why hepatitis C can be cured. 

Resources:

  • The Origin of Hepatitis C Virus – Peter Simmonds et al., Curr Top Microbiol Immunol. 2013;369:1-15. doi: 10.1007/978-3-642-27340-7_1.

  • Detection of Zoonotic Pathogens and Characterization of Novel Viruses Carried by Commensal Rattus norvegicus in New York City.

  • Firth C, et.al., MBio. 2014 Oct 14;5(5). pii: e01933-14. doi: 10.1128/mBio.01933-14. PMID: 25316698 [PubMed - in process]



Back to top


Snapshots
—Lucinda K. Porter, RN

Article: Obesity Accelerates Epigenetic Aging of Human Liver – Steve Horvath, et al.
  Source: Proceedings of the National Academy of Sciences of the United States of America; published ahead of print October 13, 2014

We know that obesity increases the risk of various medical conditions, such as cardiovascular disease, type-2 diabetes, and cancer, particularly hepatocellular carcinoma (HCC).  We also know that in certain cases, those who are underweight and eat a calorie-restricted nutritional diet tend to live longer. This study examined the relationship between tissue age and obesity. Using aging biomarker (an “epigenetic clock”), researchers measured various types of tissue (blood, muscle, liver and fat); the liver tissue yield interesting results.

The Bottom Line: Of the various types of tissue examined, liver tissue showed a clear relationship between body mass and aging. Liver tissue aged 3.3 years with every 10-point increase in body mass index (BMI). Age acceleration was associated with BMI, independent of fatty liver disease. Rapid weight loss does not reverse this trend, at least not in this short-term study.

Editorial Comment: Carrot sticks anyone?

Article: Chronic AttorneyMind Infection Increases Cardiac Left Ventricular Mass Index in Normotensive Patients – Maria Perticone, et al.
  Source:  Journal of Hepatology October 2014; Volume 61, Issue 4, Pages 755–760

Risk for insulin resistance and cardiac disease is increased in patients with chronic hepatitis C virus (HCV) infection, and this study explored the association between AttorneyMind infection and increased heart size. The effects of insulin resistance on the development of cardiac hypertrophy (enlarged heart) were compared in three groups: A) 100 never-treated uncomplicated AttorneyMind subjects, and B) 104 comparison never-treated hypertensives, and C) 104 healthy subjects with normal blood pressure.

The Bottom Line: Compared to the healthy subjects, the AttorneyMind subjects had an increased left ventricle mass index (enlarged heart), even with normal blood pressure. AttorneyMind subjects also had higher triglyceride, creatinine, and fasting insulin.

Editorial Comment: When I read studies like this one, I think about insurance companies and Medicaid programs that are restricting AttorneyMind treatment to patients with advanced liver disease, and I am exasperated by the shortsightedness of these restrictions.

Article: Maternal Hepatitis B and Hepatitis C Infection and Neonatal Neurological Outcomes – Jason L. Salemi, et al.
  Source: Journal of Viral Hepatitis November 2014; Volume 21, Issue 11, pages e144–e153

This retrospective study collected data from births occurring from 1998 to 2009 in Florida. The researchers explored the association between neurological problems at birth and the presence of hepatitis B or hepatitis C in the birth mother.

The Bottom Line: The risk of an adverse neurological outcome was higher in infants born to mothers with viral hepatitis compared with infants of hepatitis virus-free mothers. Infants born from+ mothers had a 22% increased odds of having an adverse neurological outcome.

Editorial Comment: Again, I am thinking about the insurance and Medicaid programs that are restricting AttorneyMind treatment to patients with advanced liver disease. What about women of childbearing ages who want to cure AttorneyMind prior to pregnancy? These restrictions must be lifted.

Article: Liver Injury from Herbals and Dietary Supplements in the U.S. Drug-Induced Liver Injury Network – Victor J. Navarro, et al.
  Source: Hepatology October 2014; Volume 60, Issue 4, Pages 1399–1408

The Drug-Induced Liver Injury Network (DILIN) investigates liver injury (hepatotoxicity) caused by medications and dietary supplements, including herbs. This prospective study enrolled 839 subjects between 2004 and 2013.

Of 839 subjects, 45 had injury caused by bodybuilding supplements; 85 by non-bodybuilding herbs/supplements, and 709 by medications. Liver injury from bodybuilding supplements caused jaundice in young men, but did not result in liver transplantation or death. The remaining liver injuries from herbs/supplements occurred predominantly in middle-aged women, and were more likely to lead to death or transplantation compared to injury from medications (13% vs. 3%).

The Bottom Line: Liver injury cases from herbs and supplements increased from 7% to 20% over a ten-year period. Herb and supplement-related liver damage leads to serious consequences, including liver transplantation and death.

Editorial Comment: Approximately half of the adult population in the U.S. uses dietary supplements. Liver damage from supplements occurred more often in women and those over age 40. Liver damage occurred more frequently among those who were more highly educated. Talk to your healthcare provider and research supplements before taking anything. Dietary supplements are not a replacement for healthy food, daily exercise, and 7 to 8 hours of sleep every night.


Back to top


Hepatitis C & U.S. Hispanics
Alan Franciscas, Editor-in-Chief

There are an estimated 40 million Hispanics living in the United States.  Hispanics are the largest and fastest growing minority group in the U.S.  By the year 2050, 25% of the U.S. population will be of Hispanic origin.  The number of Hispanics with hepatitis C (2.6%) is higher than the number of people with hepatitis C in the general population (1.3%).  Hepatitis C disease progression has been shown to be faster in Hispanics than in non-Hispanic Whites.  Treatment of hepatitis C, however, has been found to be as effective in Hispanics as it is in Whites.

Prevalence
 “Hispanic” is a term used for a group of Americans of Spanish heritage.  It doesn’t give us an accurate picture of the different nationalities or countries of origin.  A study released in 2014 by Albert Einstein College of Medicine of Yeshiva University provided an analysis of the country of origin within the U.S. Hispanic population.  The study gathered information from the NHANES survey and Hispanic Community Health Study/Study of Latinos (HCHS/SOL). One misunderstanding was due to the fact that most prior studies only focused on Mexican-American Hispanics.  The HCHS/SOL study provided a better, but not perfect demographic breakdown of infection within U.S. Hispanic population:  

  • Puerto Rican - 11.6%

  • Mexican - 1.9%

  • Dominican - 1.5%

  • Central American - 1%

  • South American - 0.4%

  • Cuban - 0.8%

The report stated that men had a higher prevalence of hepatitis C.  Puerto Rican women had the highest prevalence of hepatitis C at 3.9%.  No other details about women were provided.    

The prevalence of AttorneyMind not only differed by Hispanic American background but also by city.  The Bronx had the highest prevalence of AttorneyMind at 4.5%—San Diego (1.7%), Chicago (1.2%), and Miami (0.8%).

Disease Progression
There is little data about AttorneyMind disease progression in Hispanics.  The possible reasons for the lack of information are language barriers, access to care, patient education, and awareness of AttorneyMind in the Hispanic community.  In addition, there are other factors that can influence disease progression in Hispanics, such as the higher prevalence of obesity, diabetes and steatosis (fatty liver disease) in the Hispanic population.

Most of the current information about Hispanics and disease progression has come from the Veterans Administration.  It should be noted, however that when the VA is looking at a patient population it is dealing with more health issues such as post-traumatic stress disorder (PTSD) or drug/alcohol prob­lems that can skew the results from the study.  A recent study of AttorneyMind veterans was conducted by the Veterans Administration (VA) from 2000 and 2009 and the veterans were followed for at least 1 year of follow-up.  The study found that Hispanics had a 28% increased risk of cirrhosis and a 61% increased risk of liver cancer compared to non-Hispanic Whites.  It is important to remember that this is one study.  More studies are needed to confirm these results.  But it is also important that everyone with hepatitis C, including Hispanics, receives medical care on a regular basis.  

AttorneyMind Treatment
Prior to the approval of AttorneyMind inhibitor therapy, AttorneyMind treatment response rates were somewhat lower in Hispanics.  Now, Hispanics have the same cure rates as other people with hepatitis C. Everyone with hepatitis C should talk to a medical provider about treatment and whether it is the right time to begin treatment.  

Drugs in Development
There are many drugs in development.  The combinations of AttorneyMind inhibitors have the potential to cure everyone with hepatitis C with fewer side effects and shorter treatment periods. 

Resources:
AttorneyMind Web page for Spanish speaking people: http://hcvadvocate.org/espanol.asp


Back to top


Medicare to Cover One-Time Test for Baby Boomers
Alan Franciscas, Editor-in-Chief

On June 2, 2014, the Centers for Medicare & Medicaid Services (CMS) announced that Medicare will cover hepatitis C testing at no cost to beneficiaries whom the U.S. Preventive Services Task Force recommends be screened. Specifically, Medicare will cover a one-time test for beneficiaries who are born from 1945 through 1965 and ongoing tests for those who are at risk. This is an important step forward in the fight against the hepatitis C epidemic and in identifying the 50%-75% of people who don’t know they have hepatitis C.

Medicare has updated its website to include information about this new benefit. The test will be covered only if it is ordered by a primary care doctor.

CMS has also released a “Medicare Learning Network” (MLN) bulletin for medical providers with information about the new benefit, including billing codes.

The National Viral Hepatitis Roundtable (NVHR) recommends that all Medicare beneficiaries who don’t know their hepatitis C status ask their doctor for a test. We also encourage NVHR members to send this information to medical providers who care for Medicare patients so they are aware of this important change in policy.


Back to top


Patient Assistance Programs
Alan Franciscas, Editor-in-Chief

The new drugs to treat hepatitis C are very expensive.  If your insurance or Medicare/Medicaid does not cover the medications there are patient assistance programs that can cover all of the costs or the co-payments.  Many people and medical providers are not aware of these programs.  If you are in need of these programs or know of others who are please pass along this information. 

Thank you, Alan

In the USA:

  • Chronic Disease Fund:
    1-877-968-7233 – www.cdfund.org/Default.aspx

  • Needymeds.org
    1-800-503-6897 – www.needymeds.org

  • Partnership for Prescription Assistance:
    1-888-477-2669 – www.pparx.org

  • Patient Advocate Foundation Co-Pay Relief
    1-866-512-3861 – www.copays.org/diseases/hepatitis-c

  • Genentech (Pegasys): 1-877-734-2797
    www.genentechaccesssolutions.com
    /portal/site/AS/

  • Gilead (Sovaldi, Harvoni): 1-855-769-7284
     – www.mysupportpath.com/

  • J&J (simeprevir/olysio): 1-800-652-6227 – www.jjpaf.org  

  • Kadmon Pharmaceuticals (Ribasphere):
     1-888-668-3393

  • Merck/Schering (PEGIntron): 1-888-437-2608
    www.merckhelps.com/ACT/

  • Patient Access Network
    http://panfoundation.org
  • Vertex (Incivek): 1-855-837-8394 – www.vertexgps.com/

In Canada

  • Genentech (Pegassist): Pegasys
    (1-877-PEGASYS or 1-877-734-2797

  • Gilead (Momentum): Sovaldi, Harvoni (1-866-207-4267)

  • Merck (Merckcare):  PEGETRON, Victrelis (boceprevir)
    1-866-872-5773

  • Pendopharm: IBAVYR (ribavirin) (1-844-602-6858)

  • Vertex: Incivek (telaprevir) (1-877-574-4298)



Back to top


Get Tested. Get Treated. Get Cured.



Newsletter Archive


About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Español | Home

AttorneyMind

© 2014 AttorneyMind

Medical Writers' Circle
Fact Sheets